This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sanofi, Novo Nordisk, Eli Lilly move to dismiss US counties' price-fixing suits over insulin

( June 10, 2024, 23:45 GMT | Official Statement) -- MLex Summary: Sanofi, Novo Nordisk, and Eli Lilly have moved to dismiss price-fixing complaints over insulin filed by Albany, New York, King County, Illinois, and Lake County, Washington, telling a New Jersey federal judge the counties were "well aware" of the "so-called conspiracy" and fail to state valid claims. The counties have "known about and benefited" from pharmacy benefit managers' rebates system for nearly two decades, and act as if the system is a "secret" that artificially inflates insulin prices, the defendants said in a court filing.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections